Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, June 12, 2016

Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library



Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library
 

Ovarian Cancer

Gynecologic Cancer

2016 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.

2016 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. Jonathan A. Ledermann 5501
Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. David Marc Gershenson 5502
Multicenter phase II study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma. Kosei Hasegawa 5504
The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. Sandro Pignata 5505
Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. Usha Menon 5507
Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS). Felicia Roncolato 5508
Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women. Allison W. Kurian 5510
Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. Janos Laszlo Tanyi 5511
Tumor-infiltrating lymphocytes (TILs) and PDL1 expression in ovarian cancer (OC): Evolution with neoadjuvant chemotherapy (NCT) and prognostic value. Soizick Mesnage 5512
Specific gene signatures and oligo clonal expansion of b cell repertoire with responders of anti-PD-1 antibody, nivolumab for ovarian cancer: Novel predictive biomarkers. Junzo Hamanishi 5513
Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis. Kyle Strickland 5514
A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission. Paul Sabbatini 5517
Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218. Angeles Alvarez Secord 5521
Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS. Jalid Sehouli 5522
Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. Robert L. Coleman 5523
Real-time single-walled nanotube (SWNT)-based imaging system to improve tumor detection and survival in ovarian cancer preclinical model. Lorenzo Ceppi 5530
A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary. John H. Farley 5531
Veliparib monotherapy to patients with BRCA germline mutation and platinum-resistant or partially platinum-sensitive selapse of epithelial ovarian cancer: A phase I/II study. Karina Dahl Steffensen 5532
Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. Mary L. Disis 5533
Evolution in epithelial ovarian cancer (OC) trials: Improving accuracy by design. Michelle K. Wilson 5534
Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (≥70 years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study. Frédéric Selle 5535
Preliminary results from the first in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. David Michael Hyman 5536
Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). Philipp Harter 5538
Universal germline BRCA testing of ovarian cancer patients and implications for treatment. Erica Bednar 5539
Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). Robert L. Coleman 5540
Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity. John Ben Liao 5542
A phase I/II study of Enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I. Iain A. McNeish 5543
Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study). Eric Hahnen 5544
Glucocorticoid receptor expression and survival in ovarian cancer. Jennifer Taylor Veneris 5545
Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer. Kunle Odunsi 5546
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. Ursula A. Matulonis 5547
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial. Anna Piskorz 5549
P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes. Victoria Mandilaras 5550
Tumor responses and preliminary survival data in a phase II trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer. Richard T. Penson 5551
Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer. Sarah E Taylor 5552
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Bo Gao 5553
Endocrine therapy for ovarian cancer: A systematic review and meta-analysis of phase II studies. Laura Paleari 5554
A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial. Mansoor Raza Mirza 5555
Prognostic effects of clinical and tumor (t) factors in bevacizumab (BEV)-treated patients (pts) with ovarian cancer (OC). Nicoletta Colombo 5556
A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. Gottfried E. Konecny 5557
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: The EBMT experience. Ugo De Giorgi 5558
Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC). Tami Grunewald 5559
Laparoscopic versus open surgery in the treatment of apparently early stage epithelial ovarian cancer: Case-control and case-matched study of Korean Gynecologic Oncology Group. Jeong-Yeol Park 5560
Randomized trial of exercise vs. usual care on cancer biomarkers in ovarian cancer survivors: The Women’s Activity and Lifestyle Study in Connecticut (WALC). Brenda Cartmel 5561
A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors. Erika Paige Hamilton 5562
A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer. Juliet Elizabeth Wolford 5563
Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium. Victor Rodriguez Freixinos 5564
A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer. Sarah Patricia Blagden 5565
Sustained impact of primary platinum-free interval and BRCA1/2 mutation status on survival in patients with ovarian cancer after multiple lines of therapy. Michael A. Bookman 5566
IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). Kathleen N. Moore 5567
An evaluation of the microbiota of the upper genital tract of women with benign changes and epithelial ovarian cancer. Wendy R. Brewster 5568
A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC). Susana N. Banerjee 5569
Validation of a multi-marker panel for early detection of ovarian cancer. Robert C. Bast 5570
PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). Charlie Gourley 5571
Somatic alterations in the PTEN-PI3K-AKT-mTOR pathway in a cohort of 379 ovarian cancer patients. Elizabeth Stover 5572
Genomic instability (GI) score post-neoadjuvant chemotherapy (NACT) to predict overall survival (OS) in high grade ovarian cancer (HGSOC). Aurelie Auguste 5573
The impact of preoperative malnutrition on surgery outcome and overall survival in ovarian or peritoneal cancer patients: A prospective study. Jalid Sehouli 5574
Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC). Felicia Roncolato 5575
The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence. Doreen O Jackson 5576
Circulating cell-free DNA: The future of personalized medicine in ovarian cancer management. Rebecca Christian Arend 5577
A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer. Agustin A. Garcia 5578
Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome. Victoria Mandilaras 5579
Adequacy of surgical staging to predict survival in early stage ovarian cancer. Rachel Hope Occhiogrosso e17037
Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. Nicole Concin e17038
A phase I study of a p53MVA vaccine in combination with gemcitabine (GEM) in recurrent ovarian cancer (OC). Mihaela C. Cristea e17040
Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab. Christophe Boetsch e17042
Prevalence study of germline BRCA1/2 mutation in Korean patients with high-grade serous and/or endometrioid epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Eun Jin Heo e17043
ARID1A alterations in gynecological cancers as a therapeutic opportunity. Laura Gonzalez-Malerva e17044
In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts. Panagiotis Konstantinopoulos e17045
Evaluation of homeobox (HOX) gene expression as a prognostic biomarker of time to recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients treated with adjuvant carboplatin plus paclitaxel (A-C/P). Jai Narendra Patel e17046
Evaluating a novel oncologist-led BRCA1/2 mutation (BRCAm) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study. Gloria S. Huang e17048
A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors. Jason D. Lickliter e17049
PHASE II evaluation of dalantercept for persistent or recurrent epithelial ovarian and related cancers: An NRG oncology study. Robert Allen Burger e17050
Trends in ovarian cancer incidence and relative survival in the U.S. by race/ethnicity and histologic subtypes: A SEER analysis 2000-2012. Hyo K. Park e17051
Ovarian Sertoli Leydig cell tumors: a single institution series of predominantly postmenopausal women. Gregory M. Gressel e17052
Evaluation of genomic alterations in primary small cell carcinoma of the ovary (SCCO). George Yaghmour e17053
Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who received neoadjuvant treatment for advanced ovarian cancer. Trishala Meghal e17054
Improved survival of stage 4 high grade ovarian cancer patients as staged by positron emission tomography (PETCT), who undergo chemotherapy (with a good PETCT response) and debulking surgery as seen in a prospective study in our cancer institution. Chit Cheng Yeoh e17055
Characterization of CTCs isolated from patients with recurrent ovarian cancer using an antibody-free CTC isolation device. Alpa Manchandia Nick e17056
PD-1, PD-L1 in BRCA1/2-mutated and non-mutated epithelial ovarian carcinomas (EOCs). Jasgit C. Sachdev e17057
The role of clinical and surgical factors characterizing longterm-survival in ovarian cancer. Hannah Woopen e17059
Genomic characterization of high-grade serous ovarian Cancer by using targeted RNA and DNAseq gene panels. Salvador Blanch e17060
Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation. Mariana de Paiva Batista e17061
Challenges in implementing a guideline for the early diagnosis of suspected ovarian cancer in Ireland. Marie Laffoy e17062
Effect of death receptor 6 (DR6) targeted molecular ultrasound imaging on detection of ovarian tumors at early stage. Animesh Barua e17063
Treatment of gynecologic cancers in HIV+ women. Kimberly Levinson e17064
Impact of chemotherapy on survival for low risk versus high risk early stage ovarian cancer. Rachel Hope Occhiogrosso e17066
IL-6 immunomodulation by antibiotics in advanced ovarian cancer patients. Pedro ALEJANDRO Lucero-Diaz e17067
Efficacy and safety of adjuvant intraperitoneal chemotherapy in carcinoma ovary: A prospective observational study. Varun Goel e17069
Association of MiR-26b mediated doxorubicin resistance signature with poor prognosis in epithelial ovarian cancer (EOC). Ilya Korsunsky e17070
Treatment focused genetic testing (TFGT) for ovarian cancer (OC) patients: The Catalan Institute of Oncology (ICO) network experience. Maria Pilar Barretina-Ginesta e17071
Ethnic variations in ARID1a expression in clear cell and endometrioid ovarian carcinoma. Tiffany Lai e17073
Accuracy of preoperative imaging diagnosis as a possible new staging system in advanced ovarian, tubal, and peritoneal cancer: Using data from Japan Clinical Oncology Group study JCOG0602. Takashi Onda e17074
Identification of druggable targets in high-grade epithelial ovarian cancer (EOC) using next generation sequencing (NGS)–based molecular diagnostic. Jean-Louis Merlin e17076
Oncologic outcomes of advanced gynecologic malignancies managed with the aid of comprehensive genomic profiling (CGP) in a rural community setting. Luis Alexander Rojas-Espaillat e17077
Exome sequencing of ovarian cancer patients to identify variants predictive of sensitivity to chemotherapy. Assaad Semaan e17079
A phase II randomized study: Outcomes after cytoreductive surgery (CRS) with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) followed by adjuvant chemotherapy as initial treatment of advanced stage (stage III/IV) ovarian, fallopian tube, and primary peritoneal cancer. Teresa Diaz-Montes e17080
Impact of obesity on survival and recurrence of high grade serous carcinoma of the ovary. Carolina Ibañez e17081
Does time-to-chemotherapy (TTC) impact the outcomes of resected ovarian cancer? Meta-analysis of randomized and observational data. Diogo Bugano Diniz Gomes e17082
Evaluation of centrosome clustering protein KIFC1 as a potential prognostic biomarker in serous ovarian adenocarcinomas. Karuna Mittal e17083
Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target. Ruby Yun-Ju Huang e17084
Gene expression profiling of single circulating tumor cells in ovarian cancer: Establishment of a multi-marker gene panel. Tanja N. Fehm e17085
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, RAP80, HOXA9, DAXX, ERCC1, thioredoxin-1, TSP1, and TXR1 genes in patients with epithelial ovarian cancer (EOC) WHO received platinum-taxane first line therapy. Ioannis Sougklakos e17086
H2AX and topoisomerase II expression as potential predictors of response to treatment with pegylated liposomal doxorubicin in metastatic ovarian cancer. Irene Moreno Candilejo e17088
Impact of BMI on genetic variation in ovarian cancer. Tara Castellano e17090
T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer. Yuji Ikeda e17091
Toxicity related to first line, platinum-based chemotherapy in BRCA1-associated epithelial ovarian cancer: Is DNA repairing impairment associated with more adverse events? Agnieszka Badora-Rybicka e17092
Feasibility of an induced metabolic bioluminescence imaging technique in ovarian cancer: Results of a pilot study. Marco Johannes Battista e17093
Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrence ovarian cancer (ROC) patients with BRCA 1/2 mutation. A monoistitutional experience. Giuseppa Scandurra e17094
Intraperitoneal chemotherapy in pretreated ovarian cancer patients matched with patients treated with parenteral chemotherapy. Maria Ornella Nicoletto e17095
Cisplatin to induce cancer stem cell state in ovarian cancer. Caner Saygin e17098
VEGF-A and VEGF-R1 in benign and malignant ovarian tumors: Correlation with HE4 tumor marker. Valeria Bandovkina e17099
Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy after cytoreductive surgery outcome. Makoto Yamamoto e17100
OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). Helen Mackay LBA5503
CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer. Stephanie Gaillard TPS5597
SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm). Elizabeth S. Lowe TPS5598
Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162). Panagiotis Konstantinopoulos TPS5599
Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial. Eric Pujade-Lauraine TPS5600
Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Brittany Anne Davidson TPS5601
Phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two or three prior therapies. Rachel N. Grisham TPS5602
NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium. Rosalind Margaret Glasspool TPS5603
TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer. Agnieszka Michael TPS5604
Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer. Premal H. Thaker TPS5605
A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. Antonio Gonzalez-Martin TPS5606
PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Isabelle Ray-Coquard TPS5607
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer. Thomas J. Herzog TPS5608
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer. Beverly Long TPS5609
WEE WIN: Window of opportunity study of induction Wee1 inhibition in advanced high-grade serous ovarian cancer. Shannon Neville Westin TPS5610
FORWARD II: A phase Ib study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FRα)-positive advanced epithelial ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial cancer. David M. O'Malley TPS5611
Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer. Robert Michael Wenham TPS5612

0 comments :

Post a Comment

Your comments?